Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.

Published by献岸 苍 Modified over 4 years ago

Similar presentations

Presentation on theme: "Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model."— Presentation transcript:

1 Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.
Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model. Fifteen xenograft-bearing mice were treated for 3 to 10 days with ABI 196 mg/kg twice daily (b.i.d), VT mg/kg twice daily, or vehicle and tumors were harvested. All mice were sacrificed approximately 3 hours after last dose (for details, see Materials and Methods). mRNA transcript levels of AR-related transcripts in tumor samples were evaluated with qRT-PCR relative to GAPDH (A). Western blot analysis for AR, PSA, and CYP17A1 levels demonstrates significant tumor heterogeneity between tumors from individual mice (B). Intratumoral drug levels for ABI and VT-464 as measured using LC-MS chromatography in triplicate (C). Steroid analysis results for androgens and upstream precursors (D). Paul J. Toren et al. Mol Cancer Ther 2015;14:59-69 ©2015 by American Association for Cancer Research

Download ppt "Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model."

Similar presentations

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.
Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
CHK1 downregulation upon ERG overexpression.

CHK1 downregulation upon ERG overexpression.
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.
A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.

A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.
Overexpression of HGF decreases MET protein levels.

Overexpression of HGF decreases MET protein levels.
Activity of MAC-321 (i. v. and p. o

Activity of MAC-321 (i. v. and p. o
Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.

Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.
Effect of MI-773 dosing on long-term efficacy.

Effect of MI-773 dosing on long-term efficacy.
In vivo growth inhibition elicited by afatinib and GSK2849330 in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.

In vivo growth inhibition elicited by afatinib and GSK in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.
Effects of Z-FA-FMK on SMN protein expression in type II SMA patient fibroblast cells (GM22592). Effects of Z-FA-FMK on SMN protein expression in type.

Effects of Z-FA-FMK on SMN protein expression in type II SMA patient fibroblast cells (GM22592). Effects of Z-FA-FMK on SMN protein expression in type.
ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.

ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.
Nrf2−/− mice had higher TGF-β1 transcription and FN expression.

Nrf2−/− mice had higher TGF-β1 transcription and FN expression.

Similar presentations

Ads by Google